

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

CEQUA
(cyclosporine ophthalmic solution)

RESTASIS
(cyclosporine ophthalmic emulsion)

Status: CVS Caremark Criteria
Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATION

Cequa

Cequa is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Restasis

Restasis is a topical immunomodulator indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for dry eye disease
- AND**
- Patient has experienced an inadequate treatment response, intolerance, or contraindication to artificial tears products

REFERENCES

1. Cequa [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; August 2018
2. Restasis [package insert]. Irvine, CA: Allergan, Inc; July 2017.
3. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed October 2017.
4. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed October 2017.
5. Preferred Practice Pattern. Dry Eyes Syndrome. American Academy of Ophthalmology. September 2013.
6. Roberts CW, et al. Comparison of Topical Cyclosporine, Punctal Occlusion, and a Combination for the Treatment of Dry Eye. *Cornea* 2007; 26(7):805-809.